Relmada Therapeutics (NASDAQ: RLMD) stock surged approximately 80% in pre-market trading after the company announced positive mid-stage data from a Phase 2 clinical trial of its bladder cancer drug NDV-01 and simultaneously completed a $160 million private placement. The trial showed a 12-month complete remission rate of 76% for NDV-01, and the company plans to initiate a Phase 3 clinical trial by mid-2026. The financing was led by multiple investment firms and is expected to close around March 11, 2026, enabling the company to sustain operations until 2028.

🚨 Crude Oil Above $110: Is This the Start of a New Energy Supercycle? A Trader’s Perspective
#GateFebruaryTransparencyReport $BTC $ETH
The global energy market has once again captured the attention of traders and investors worldwide. In a dramatic overnight rally, crude oil prices surged sharply, pushing WTI above $110 and Brent crude beyond $110, levels that immediately reignited discussions about supply shocks, geopolitical tensions, and the possibility of a longer-term energy bull market.
For many traders, this move was not just another headline—it was a moment that highlighted how quickl